Tesla’s board found a way to get rich without getting “paid.” The company suspended director compensation in 2021 after shareholders sued, but earlier option grants kept swelling with the stock. A Reuters analysis with Equilar finds Tesla directors still averaged about $1.7 million a year from 2018 to 2024 — and logged more than $3 billion in stock-award gains from 2004 to 2024 — a haul that far out-muscles peer boards across Big Tech. Tesla relied heavily on stock options for director compensation, issu ...

A JetBlue passenger jet bound for New York took evasive action on Friday to avoid a mid-air collision with a U.S. Air Force plane near Venezuela, a pilot said in an air traffic control recording. ...

Norwegian Cruise Line Holdings Ltd's (NYSE:NCLH) stock just flashed a signal traders rarely ignore — and it comes at an awkward moment. NCLH has now printed a Death Cross, with the 50-day moving average slipping below the 200-day, signaling that short-term momentum has overtaken the longer-term trend to the downside.Track NCLH stock here.The stock is already down about 18% year to date, with selling pressure intensifying over the past month. Yet the chart isn't collapsing outright — setting up a tense momen ...

Despite a recent pullback, shares are still up big over the past year, and one investor seems to be expecting further upside.Dallas-based Permian Investment Partners initiated a new position in Resideo Technologies (REZI), adding 965,936 shares valued at approximately $41.7 million, according to a November 14 SEC filing.What HappenedPermian Investment Partners disclosed a new equity stake in Resideo Technologies (REZI +0.47%) in its quarterly portfolio update filed with the Securities and Exchange Commissio ...

The U.S. Federal Trade Commission said it and 21 states, along with the District of Columbia, have filed an amended complaint against ride-hailing app Uber alleging it engaged in deceptive billing and... ...

It is insane to look at Oracle Corporation ( ORCL ) right now and realize that the stock is up only 10% year-to-date, which is a staggering underperformance relative to how we were feeling only a couple of months back, when Oracle stockI write about stocks I’m personally interested in adding to my portfolio. I’m not a professional advisor, but I study business and economics and analyze markets full-time. My writing is meant for both complete beginners — I avoid unnecessary complexity — and advanced readers, ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Lamb Weston (LW) , which belongs to the Zacks Food - Miscellaneous industry.This frozen foods supplier has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 36.49%.For the most recent quarter, Lamb Weston was expected to post earnings of ...

It is insane to look at Oracle Corporation ( ORCL ) right now and realize that the stock is up only 10% year-to-date, which is a staggering underperformance relative to how we were feeling only a coupleI write about stocks I’m personally interested in adding to my portfolio. I’m not a professional advisor, but I study business and economics and analyze markets full-time. My writing is meant for both complete beginners — I avoid unnecessary complexity — and advanced readers, as I always aim to offer a distin ...

The company plans to sell its Luminar Semiconductors subsidiary to Quantum Computing for $110 million. ...

Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ:SNY) . The new agreement is built on the existing relationship between the two companies, following Sanofi’s acquisition earlier this year of Dren Bio’s DR-0201 program for deep B-cell depletion. • Sanofi shares are experiencing downward pressure. Why are SNY shares declining?The collaboration covers the discovery and development of a next-generation B-cell depleting therapy for the treatment of ...